

CHIEF MEDICAL OFFICER APPOINTED TO LEAD CLINICAL DEVELOPMENT AND MEDICAL AFFAIRS

MELBOURNE, Australia, 07 February 2022: Dimerix Limited (ASX: DXB), a biopharmaceutical company with three ongoing Phase 3 clinical studies in kidney and respiratory inflammatory diseases, today announced the appointment of Dr Ash Soman, MD, as Chief Medical Officer (CMO) and a member of the Company's executive management team.

Dr Soman will lead the Company's multiple global clinical development programs and medical affairs at a pivotal time in Dimerix evolution.

Dr Soman, a highly experienced clinician, has over 30 years' experience spanning hospital clinical practice, clinical study design, medical affairs, compliance, patient safety and corporate strategy, having worked in big pharma, small biotech and clinical research organisations (CRO). Dr Soman has prior clinical training in general and respiratory medicine, working with patients suffering from both chronic kidney and respiratory diseases, and has assisted drug launches for the SGLT2 inhibitor dapagliflozin (indicated in diabetes and kidney disease) and coronary artery disease.

Most recently, Dr Soman was the Medical Director for the global CRO, IQVIA, where he managed strategy, early phase clinical trial design, development and oversight for emerging biotech companies in multiple therapy areas, including COVID-19. He previously held roles with AstraZeneca (Medical Director, Cardiovascular & Diabetes), Sanofi-Aventis Australia-New Zealand, Oncosil Medical and Roche.

Dr Soman, who is based in Australia, holds a Bachelor of Medicine and Surgery (MBBS) from the University of London, and an MBA and Diploma of Imperial College (DIC) from The Business School, Imperial College of Science, Technology and Medicine, London. He is also a Member of the Royal College of Physicians – London (MRCP) and has published in a number of notable medical journals.

"As we enter a new chapter in the Dimerix story and progress through the final stages of development towards commercialisation, we are delighted to welcome Ash to the team. Ash's diverse background will further boost Dimerix' core competencies and, with Ash's appointment, Dimerix has completed the executive team build out to deliver maximum value from our assets."

Dr Nina Webster, Dimerix CEO & Managing Director

"I am delighted to be joining the team at Dimerix at an exciting time. I believe that Dimerix has the potential to deliver substantial value to patients with both chronic renal and respiratory diseases moving forward, as well as our employees, investors and the wider community."

Dr Ash Soman, incoming Chief Medical Officer

Dr Soman will transition to full time following completion of his notice requirements from his prior role – expected to be no later than 25th April 2022.

For further information, please visit our website at www.dimerix.com or contact:

Dr Nina Webster
Dimerix Limited
Chief Executive Officer & Managing Director
Tel: +61 1300 813 321
E: investor@dimerix.com

Rudi Michelson
Monsoon Communications
Tel: +61 3 9620 3333
Mob: +61 (0)411 402 737
E: rudim@monsoon.com.au

Follow us on [LinkedIn](#) and [Twitter](#)

Authorised for lodgement by the Board of the Company

—END—

About Dimerix

Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company developing innovative new therapies in areas with unmet medical needs for global markets. Dimerix is currently developing its proprietary product DMX-200, for Focal Segmental Glomerulosclerosis (FSGS), respiratory complications associated with COVID-19 and Diabetic Kidney Disease, and is developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). DMX-200 and DMX-700 were both identified using Dimerix' proprietary assay, Receptor Heteromer Investigation Technology (Receptor-HIT), which is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. Receptor-HIT is licensed non-exclusively to Excellerate Bioscience, a UK-based pharmacological assay service provider with a worldwide reputation for excellence in the field of molecular and cellular pharmacology.

ESG Statement: *Dimerix is committed to integrating Environmental, Social and Governance (ESG) considerations across the development cycle of its programs, processes and decision making - being alert and responsive to the challenges and opportunities of doing business responsibly and sustainably.*

About DMX-200

DMX-200 is the adjunct therapy of a chemokine receptor (CCR2) antagonist administered to patients already receiving an angiotensin II type I receptor (AT1R) blocker - the standard of care treatment for hypertension and kidney disease. DMX-200 is protected by granted patents in various territories until 2032.

In 2020, Dimerix completed two Phase 2 studies: one in FSGS and one in diabetic kidney disease, following a successful Phase 2a study in patients with a range of chronic kidney diseases in 2017. No significant adverse safety events were reported in any study, and all studies resulted in encouraging data that could provide meaningful clinical outcomes for patients with kidney disease. DMX-200 is also under investigation as a potential treatment for patients with COVID-19 in two separate studies: REMAP-CAP and CLARITY 2.0.